| Title |
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
|
|---|---|
| Published in |
Breast cancer targets and therapy, September 2015
|
| DOI | 10.2147/bctt.s90627 |
| Pubmed ID | |
| Authors |
Pooja Advani, Lauren Cornell, Saranya Chumsri, Alvaro Moreno-Aspitia |
| Abstract |
Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase transmembrane receptor that is overexpressed on the surface of 15%-20% of breast tumors and has been associated with poor prognosis. Consistently improved pathologic response and survival rates have been demonstrated with use of trastuzumab in combination with standard chemotherapy in both early and advanced breast cancer. However, resistance to trastuzumab may pose a major problem in the effective treatment of HER2-positive breast cancer. Dual HER2 blockade, using agents that work in a complimentary fashion to trastuzumab, has more recently been explored to evade resistance in both the preoperative (neoadjuvant) and adjuvant settings. Increased effectiveness of dual anti-HER2 agents over single blockade has been recently reported in clinical studies. Pertuzumab in combination with trastuzumab and taxane is currently approved in the metastatic and neoadjuvant treatment of HER2-positive breast cancer. Various biomarkers have also been investigated to identify subsets of patients with HER2-positive tumors who would likely respond best to these targeted therapy combinations. In this article, available trial data regarding efficacy and toxicity of treatment with combination HER2 agents in the neoadjuvant and adjuvant setting have been reviewed, and relevant correlative biomarker data from these trials have been discussed. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| Denmark | 1 | 1% |
| Czechia | 1 | 1% |
| Austria | 1 | 1% |
| Unknown | 72 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 20% |
| Student > Master | 11 | 14% |
| Student > Ph. D. Student | 10 | 13% |
| Other | 8 | 11% |
| Student > Bachelor | 7 | 9% |
| Other | 12 | 16% |
| Unknown | 13 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 43% |
| Agricultural and Biological Sciences | 10 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Biochemistry, Genetics and Molecular Biology | 4 | 5% |
| Social Sciences | 3 | 4% |
| Other | 6 | 8% |
| Unknown | 15 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 December 2023.
All research outputs
#1,792,735
of 25,368,786 outputs
Outputs from Breast cancer targets and therapy
#15
of 324 outputs
Outputs of similar age
#23,346
of 276,775 outputs
Outputs of similar age from Breast cancer targets and therapy
#1
of 10 outputs
Altmetric has tracked 25,368,786 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 324 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,775 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them